Steps taken after granting the Marketing Authorisation 
For procedures finalised after  1 October 2004 please refer to module 8B. 
•  The MAH submitted on 22 April 1999, an application for a Notification of a Type I variation No 
20  of  Annex  I,  in  order  to  change  the  shelf-life  of  the  finished  product  from  12  to  18  months, 
pursuant to Article 4 of Commission Regulation (EC) No 542/95 of 10 March 1995 as amended. 
The  procedure  started  on  30  April  1999.  The  positive  notification  was  signed  by  the  Head  of 
Human  Medicines  Evaluation  Unit  at  the  EMEA  on  26  May  1999  (EMEA/H/C/207/I/01)  and 
forwarded  to  the  European  Commission  which  amended  the  Commission  Decision  on  29  July 
1999. 
•  The MAH submitted on 6 April 1998, an application for a Notification of a Type I variation No 20 
of Annex I, in order to change the shelf-life of the active substance from 6 to 12 months, pursuant 
to  Article  4  of  Commission  Regulation  (EC)  No  542/95  of  10  March  1995  as  amended.  The 
procedure started on 30 April 1999. The positive notification was signed by the Head of Human 
Medicines  Evaluation  Unit  at  the  EMEA  on  26  May  1999  (EMEA/H/C/207/I/02)  and  was 
forwarded to the European Commission. 
•  The MAH submitted on 22 April 1999, an application for two Type I variations No 24 and a Type 
I variation No 14 with a consequential variation No 17 of Annex I, (type II procedure applicable) 
in  order  to  change  the  specifications  and  test  procedures  of  the  active  substance  and  medicinal 
product,  pursuant  to Article 4 of Commission  Regulation (EC)  No 542/95  of  10 March  1995 as 
amended.  The  procedures  started  on  26  April  1999  and  positive  opinions  were  adopted  by  the 
CPMP  on  24  June  1999  (EMEA/H/C/207/I/03-05)  and  forwarded  to  the  European  Commission, 
which amended the Commission Decision on 22 September 1999. 
•  The MAH submitted on 6 April 1999, a Notification to the EMEA in order to introduce changes to 
the Package Leaflet not connected to the Summary of Product Characteristics, pursuant to Article 
10(3) of Council Directive No. 92/27/EEC of 31 March 1992. The procedure started on 30 April 
1999. The positive Notification was signed by the Head of Human Medicines Evaluation Unit at 
the  EMEA  on  26  May  1999  (EMEA/H/C/207/N/06).  The  European  Commission  amended  the 
annexes to the Commission Decision on 29 July 1999. 
•  The MAH submitted on 11 October 1999, an application for a Notification of a Type I variation 
No 20 of Annex I, in order to extend the self-life of the medicinal product, pursuant to Article 4 of 
Commission Regulation (EC) No 542/95 of 10 March 1995 as amended. The procedure started on 
15 October 1999. A positive Notification was signed by the Head of Human Unit at the EMEA on 
12  November  1999  (EMEA/H/C/207/I/07)  and  forwarded  to  the  European  Commission,  which 
amended the Commission Decision on 8 February 2000. 
•  The MAH submitted on 11 October 1999, an application for a Type I variation No 20a of Annex I, 
in order to extend the shelf-life or re-test period of the active substance, pursuant to Article 4 of 
Commission Regulation (EC) No 542/95 of 10 March 1995 as amended. The procedure started on 
15 October 1999. A positive opinion was signed by the Head of Human Unit at the EMEA on 12 
November  1999  (EMEA/H/C/207/I/08)  and  forwarded  to  the  European  Commission,  which 
amended the Commission Decision on 15 December 1999. 
•  The MAH submitted on 21 September 1999, an application for a Type I variation No 1 and two 
consequential  application  for  Type  I  variations,  Nos  15  and  16  of  Annex  I,  (type  II  procedure 
applicable) in order to change the content of the manufacturing authorisation, the manufacture of 
the  medicinal  product  and  the  batch  size  of  the  finished  product,  pursuant  to  Article  4  of 
Commission Regulation (EC) No 542/95 of 10 March 1995 as amended. The procedure started on 
22  October  1999  and  a  positive  opinion  was  adopted  by  the  CPMP  on  16  February  2000 
(EMEA/H/C/207/I/09)  and  forwarded  to  the  European  Commission,  which  amended  the 
Commission Decision on 17 May 2000. 
1/3 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
•  The  MAH  submitted  on  3  December  1999,  an  application  for  two  Type  I  variations  No  24  of 
Annex  I,  (type  II  procedure  applicable)  in  order  to  change  test  procedure  of  active  substance, 
pursuant to Article 4 of Commission Regulation (EC) No 542/95 of 10 March 1995 as amended. 
The procedure started on 17 December 1999 and a positive opinion was adopted by the CPMP on 
16 February 2000 (EMEA/H/C/207/I/10-11) and forwarded to the European Commission, which 
amended the Commission Decision 17 May 2000. 
•  The MAH submitted on 3 December 1999, an application for a Type I variation No 25 of Annex I, 
(type  II  procedure  applicable)  in  order  to  change  the  test  procedures  of  the  medicinal  product, 
pursuant to Article 4 of Commission Regulation (EC) No 542/95 of 10 March 1995 as amended. 
The procedure started on 17 December 1999 and a positive opinion was adopted by the CPMP on 
16  February  2000  (EMEA/H/C/207/I/12)  and  forwarded  to  the  European  Commission,  which 
amended the Commission Decision on 17 May 2000. 
•  The MAH submitted on 3 February 2000 an application for a Type II variation at the request of 
the  CPMP  following  the  evaluation  of  the  3rd  PSUR,  in  order  to  modify  the  SPC  and  Package 
Leaflet,  pursuant  to  Article  6  of  Commission  Regulation  (EC)  No  542/95  of  10  March  1995  as 
amended. The procedure started on 18 February 2000 and a positive opinion was adopted by the 
CPMP on 12 April 2000. The European Commission granted a Commission Decision on 11 July 
2000 (EMEA/H/C/207/II/13). 
•  The MAH submitted on 28 March 2000 an application for a Type II variation, in order to extend 
the  current  indication  of  Simulect  to  paediatric  patients,  pursuant  to  Article  6  of  Commission 
Regulation  (EC)  No  542/95  of  10  March  1995.  The  procedure  started  on  14  April  2000, 
supplementary information was supplied by the MAH on 11 July 2000 and a positive opinion was 
adopted  by  the  CPMP  on  26  July  2000  (EMEA/H/C/207/II/14).  The  European  Commission 
granted a Commission Decision on 1 December 2000. 
•  The  MAH  submitted  on  28  March  2000  an  application  for  a  Type  II  variation,  in  order  to  use 
Simulect  together  with  a  triple  immunosuppression,  pursuant  to  Article  6  of  Commission 
Regulation  (EC)  No  542/95  of  10  March  1995.  The  procedure  started  on  14  April  2000, 
supplementary information was supplied by the MAH on 11 July 2000 and a positive opinion was 
adopted  by  the  CPMP  on  26  July  2000  (EMEA/H/C/207/II/15).  The  European  Commission 
granted a Commission Decision on 1 December 2000.  
•  The MAH submitted on  28 March 2000 an application for a Type II variation, for an additional 
method  of  administration  (iv  bolus  injection),  pursuant  to  Article  6  of  Commission  Regulation 
(EC)  No  542/95  of  10  March  1995.  The  procedure  started  on  14  April  2000,  supplementary 
information was supplied by the MAH on 11 July 2000 and a positive opinion was adopted by the 
CPMP  on  26  July  2000  (EMEA/H/C/207/II/16).  The  European  Commission  granted  a 
Commission Decision on 1 December 2000. 
2/3 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
For procedures finalised after 1 October 2004 please refer to module 8B. 
Scope 
Application 
number 
Type of 
modification1 
Notification/ 
Opinion 
issued on2 
of 
the  manufacturing 
following  modification(s) 
following  modification(s) 
Extension of shelf-life or retest period of the active substance. 
Extension of shelf-life as foreseen at time of authorisation. 
Change 
authorisation(s). 
Minor change of manufacturing process of the active substance. 
Minor change of manufacturing process of active substance.  
Minor change in labelling or package leaflet not connected with the 
SPC (Art. 61.3 Notification). 
Change 
authorisation(s). 
Minor changes in manufacture of the medicinal product. 
Changes to comply with supplements to pharmacopoeias. 
Changes to comply with supplements to pharmacopoeias. 
Centralised line extension for the new strength (10 mg) of Simulect, 
initially approved in 20 mg dosage strength. 
Changes to comply with supplements to pharmacopoeias. 
Change(s)  to  the  test  method(s)  and/or  specifications  for  the  active 
substance. 
Change(s) to the test method(s) and/or specifications for the finished 
product. 
the  manufacturing 
of 
Changes in sections 4.4, 4.8 and 5.1 of the SPC to include the long-
term data of the pivotal studies CHIB 201-E-01 and CHIB 352-E-01 
(particularly the five year safety and the general efficacy, further to 
the request of the CPMP on June 2002).  
Moreover,  inclusion  of  QRD  comments  to  the  SPC,  PL  and 
Labelling  as  previously 
line  extension. 
In  addition,  inclusion  of  minor  corrections  in  section  4.8  of  both 
strengths in line with the Core Data Sheet. 
Finally,  inclusion  of  linguistic  corrections  to  the  Italian  20mg 
strengths SPC and PL. 
Change  in  the  name  of  the  Manufacturing  Authorisation  Holder 
responsible for the batch release. 
in  Simulect  10mg 
Renewal of the Marketing Authorisation  
Minor  change  to  the  package  leaflet  not  connected  to  the  SPC,  to 
include  the  local  representatives  of  the  MAH  for  all  10  new 
European Member States, to change  the contact details for all local 
representatives  to  include  only  the  company  name  and  telephone 
number in accordance with the latest EMEA/QRD template, and the 
change of contact for Iceland. (Art. 61.3 Notification) 
I/0017 
I/0018 
I/0019 
I-0020 
I-0021 
N/0022 
I/0023 
I/0024 
I/0025 
X-0026 
I-0027 
II-0028 
II-0029 
II-0031 
I-0032 
R-033 
N-034 
Commission 
Decision 
Issued/amen
ded on 
05.02.01 
26.03.01 
05.02.01 
27.02.02 
27.02.02 
02.04.02 
- 
- 
07.03.02 
- 
25.10.02 
I 
I 
I 
I 
I 
N 
I 
I 
I 
Annex II 
application 
I 
II 
25.01.01 
25.01.01 
25.01.01 
15.11.01 
15.11.01 
21.01.02 
18.10.01 
18.10.01 
18.10.01 
21.11.02 
21.08.02 
17.10.02 
II 
II 
I 
R 
N 
19.09.02 
25.09.02 
20.02.03 
23.05.03 
15.04.03 
04.06.03 
24.07.03 
20.10.03 
03.05.04 
- 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a 
minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor 
variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II 
application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 
of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
3/3 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                            
 
